View Clinical Trial (Medical Research Study)


A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia - NCT00977522-90720(Clinical Trial 475904)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Los Alamitos
State:  
CA
Zip Code: 90720
Conditions: Schizophrenia
Purpose: This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
Study summary:
Criteria: Inclusion Criteria: - Subjects must have a current diagnosis of schizophrenia of paranoid (295.30), disorganized (295.10), or undifferentiated (295.90) subtype in the residual phase. - Subjects must be in ongoing maintenance antipsychotic monotherapy with risperidone, olanzapine, quetiapine, ziprasidone, paliperidone, or aripiprazole. Subjects must be on a stable medication treatment regimen for at least 2 months. - Evidence of stable symptomatology at least 3 months. Exclusion Criteria: - Female subjects who are pregnant or breastfeeding. - Subjects with evidence or history of a clinically significant medical condition which would increase risk or which could interfere with the interpretation of trial results. - Subjects who have DSM IV defined psychoactive substance dependence (including alcohol and excluding nicotine and caffeine dependence) within 12 months of screening or substance abuse within 3 months prior to screening.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: May 21, 2010
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.